Basilea Pharmaceutica AG/ CH0011432447 /
| 2024-04-10 7:56:01 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 44.4500USD | - | 100 Turnover: 4,422.5000 |
-Bid Size: - | -Ask Size: - | 576.28 mill.USD | - | - |
GlobeNewswire
04-24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
04-09
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
04-04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
03-11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
02-13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
01-19
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
2023-12-11
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
2023-11-20
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
2023-11-13
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
2023-10-31
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
2023-10-19
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
2023-10-17
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
2023-10-02
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire
2023-09-28
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire
2022-03-08
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire
2022-02-15
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
2022-01-24
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire
2022-01-13
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire
2022-01-11
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire
2022-01-10
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
